Literature DB >> 18591272

Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Warren E Rose1, Steven N Leonard, Michael J Rybak.   

Abstract

The need to investigate novel dosing regimens and combinations is essential in combating poor treatment outcomes for Staphylococcus aureus bacteremia and endocarditis. We evaluated the impact of simulated standard- and high-dose daptomycin in combination with gentamicin or rifampin against daptomycin-susceptible and nonsusceptible matched strains of S. aureus. These strains were collected from the daptomycin bacteremia and endocarditis clinical trial and consisted of three susceptible strains (MIC, 0.25 mg/liter) and four nonsusceptible isolates (MICs, 2 to 4 mg/liter). Daptomycin regimens of 6 and 10 mg/kg of body weight daily alone and in combination with gentamicin at 5 mg/kg daily or rifampin at 300 mg every 8 h were evaluated using an in vitro model with simulated endocardial vegetations over 96 h. Rapid bactericidal activity, identified by time to 99.9% kill, was displayed in all regimens with the daptomycin-susceptible strains. Concentration-dependent activity was noted by more-rapid killing with the 10-mg/kg/day dose. The addition of gentamicin improved activity in the majority of susceptible isolates. Daptomycin 6-mg/kg/day monotherapy displayed bactericidal activity for only one of the nonsusceptible isolates and for only two isolates with increased doses of 10 mg/kg/day. Combination regimens demonstrated improvement with some but not all nonsusceptible isolates. Three isolates developed a reduction in daptomycin susceptibility with 6-mg/kg/day monotherapy, but this was suppressed with both combination therapy and high-dose daptomycin. These results suggest that high-dose daptomycin therapy and combination therapy may be reasonable treatment options for susceptible isolates; however, more investigations are needed to confirm the variability of these regimens with nonsusceptible isolates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591272      PMCID: PMC2533470          DOI: 10.1128/AAC.00102-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.

Authors:  Kim Credito; Gengrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Authors:  Lisa Friedman; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

6.  Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

7.  Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Authors:  Francisco M Marty; Wendy W Yeh; Christine B Wennersten; Lata Venkataraman; Esperanza Albano; Edwin P Alyea; Howard S Gold; Lindsey R Baden; Satish K Pillai
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

8.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

9.  Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.

Authors:  Mark Benvenuto; David P Benziger; Sara Yankelev; Gloria Vigliani
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

10.  Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Authors:  George Sakoulas; Warren Rose; Michael J Rybak; Satish Pillai; Jeff Alder; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2007-11-14       Impact factor: 5.948

View more
  33 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.

Authors:  Kerry L LaPlante; Suzanne Woodmansee
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  High-dose daptomycin monotherapy cures Staphylococcus epidermidis 'endotipsitis' after failure of conventional therapy.

Authors:  Julia Marie Colston; Matthew Scarborough; Jane Collier; Ian C J W Bowler
Journal:  BMJ Case Rep       Date:  2013-04-16

5.  Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections.

Authors:  Warren E Rose; Andrew D Berti; Jacob B Hatch; Dennis G Maki
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

6.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

7.  Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.

Authors:  H F Chambers; L Basuino; B A Diep; J Steenbergen; S Zhang; P Tattevin; J Alder
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE).

Authors:  B A Cunha; F M Pherez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-28       Impact factor: 3.267

10.  Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  J M Miró; C García-de-la-Mària; Y Armero; D Soy; A Moreno; A del Río; M Almela; M Sarasa; C A Mestres; J M Gatell; M T Jiménez de Anta; F Marco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.